Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...